Global Markets Direct’s, 'Von Willebrand Disease - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Von Willebrand Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Von Willebrand Disease. Von Willebrand Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Von Willebrand Disease. - A review of the Von Willebrand Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Von Willebrand Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Von Willebrand Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Von Willebrand Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Von Willebrand Disease - Pipeline Review, H1 2013 Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Von Willebrand Disease Overview 6 Therapeutics Development 7 An Overview of Pipeline Products for Von Willebrand Disease 7 Von Willebrand Disease Therapeutics under Development by Companies 9 Late Stage Products 10 Comparative Analysis 10 Mid Clinical Stage Products 11 Comparative Analysis 11 Pre-Clinical Stage Products 12 Comparative Analysis 12 Von Willebrand Disease Therapeutics - Products under Development by Companies 13 Companies Involved in Von Willebrand Disease Therapeutics Development 14 Baxter International Inc. 14 Glenmark Pharmaceuticals Ltd. 15 Pfizer Inc. 16 CSL Limited 17 Von Willebrand Disease - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Drug Profiles 23 beroctocog alfa - Drug Profile 23 Product Description 23 Mechanism of Action 23 RandD Progress 23 beroctocog alfa - Drug Profile 25 Product Description 25 Mechanism of Action 25 RandD Progress 25 oprelvekin - Drug Profile 27 Product Description 27 Mechanism of Action 27 RandD Progress 27 GBR-600 - Drug Profile 28 Product Description 28 Mechanism of Action 28 RandD Progress 28 vonicog alfa - Drug Profile 29 Product Description 29 Mechanism of Action 29 RandD Progress 29 Von Willebrand Disease Therapeutics - Drug Profile Updates 30 Von Willebrand Disease Therapeutics - Dormant Products 32 Von Willebrand Disease - Product Development Milestones 33 Featured News and Press Releases 33 May 30, 2013: CSL Behring Receives CHMP Positive Opinion For Voncento For Prevention And Treatment Of Bleeding In Patients With Haemophilia A And Von Willebrand Disease 33 Oct 13, 2011: Baxter Initiates Phase III Trial Of Investigational BAX 111 For Treatment Of von Willebrand Disease 34 Dec 06, 2010: Baxter Reports Interim Data From Phase I Combination Study Of rVWF In von Willebrand Disease 34 Apr 14, 2010: Baxter Marks World Hemophilia Day by Reaffirming Ongoing Commitment to Partnering with Community to Raise Standard of Hemophilia Care Around the World 35 Feb 04, 2010: CSL Behring Announces That Global SWIFT Studies Will Evaluate Safety And Efficacy Of Biostate For Von Willebrand Disease And Hemophilia A 36 Dec 11, 2006: Baxter Announces Therapeutic Development Program for First Blood-Free Recombinant Von Willebrand Factor 37 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 40 Disclaimer 40
List of Tables
Number of Products Under Development for Von Willebrand Disease, H1 2013 7 Products under Development for Von Willebrand Disease - Comparative Analysis, H1 2013 8 Number of Products under Development by Companies, H1 2013 9 Comparative Analysis by Late Stage Development, H1 2013 10 Comparative Analysis by Mid Clinical Stage Development, H1 2013 11 Comparative Analysis by Pre-Clinical Stage Development, H1 2013 12 Products under Development by Companies, H1 2013 13 Baxter International Inc., H1 2013 14 Glenmark Pharmaceuticals Ltd., H1 2013 15 Pfizer Inc., H1 2013 16 CSL Limited, H1 2013 17 Assessment by Monotherapy Products, H1 2013 18 Assessment by Stage and Route of Administration, H1 2013 20 Assessment by Stage and Molecule Type, H1 2013 22 Von Willebrand Disease Therapeutics - Drug Profile Updates 30 Von Willebrand Disease Therapeutics - Dormant Products 32
List of Figures
Number of Products under Development for Von Willebrand Disease, H1 2013 7 Products under Development for Von Willebrand Disease - Comparative Analysis, H1 2013 8 Products under Development by Companies, H1 2013 9 Late Stage Products, H1 2013 10 Mid Clinical Stage Products, H1 2013 11 Pre-Clinical Stage Products, H1 2013 12 Assessment by Monotherapy Products, H1 2013 18 Assessment by Route of Administration, H1 2013 19 Assessment by Stage and Route of Administration, H1 2013 20 Assessment by Molecule Type, H1 2013 21 Assessment by Stage and Molecule Type, H1 2013 22